Sands Capital Alternatives, LLC
Position in ABOS — Acumen Pharmaceuticals, Inc.
CIK 1846444
ARLINGTON, VA
Position in ABOS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$9,932,680
+$1,153,233 QoQ
Shares Held
3,720,105
0.0% QoQ
Ownership
5.14%
of shares outstanding
% of Portfolio
1.62%
of 13F equity value
Holder Rank
#2
of 96 holders
Holding Since
Dec 2021
19 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABOS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Sands Capital Alternatives, LLC holds $126,924,003 across 8 Biotechnology names. ABOS ranks #4 (7.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SGP |
SpyGlass Pharma, Inc.
|
2,500,012 | $55,650,267 | |
| 2 | IKT |
Inhibikase Therapeutics, Inc.
|
13,018,965 | $26,428,498 | |
| 3 | ODTX |
Odyssey Therapeutics, Inc.
|
875,000 | $16,371,250 | |
| 4 | ABOS |
Acumen Pharmaceuticals, Inc.
This page
|
3,720,105 | $9,932,680 | |
| 5 | TARS |
Tarsus Pharmaceuticals, Inc.
|
85,000 | $5,349,900 | |
| 6 | TSHA |
Taysha Gene Therapies, Inc.
|
724,873 | $4,936,385 | |
| 7 | CADL |
Candel Therapeutics, Inc.
|
405,837 | $4,180,121 | |
| 8 | ACRV |
Acrivon Therapeutics, Inc.
|
2,289,271 | $4,074,902 |
All Filings in ABOS
Export CSV
20 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,932,680 | 3,720,105 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $8,779,447 | 3,720,105 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $7,210,028 | 3,417,075 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $5,843,198 | 3,417,075 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $3,963,807 | 3,417,075 | Shares | Sole | 2025-08-13 | |
| 2025-06-30 | $3,963,807 | 3,417,075 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $3,758,782 | 3,417,075 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $5,877,369 | 3,417,075 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $8,474,346 | 3,417,075 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $8,269,321 | 3,417,075 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $13,839,153 | 3,417,075 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $13,121,568 | 3,417,075 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $14,180,861 | 3,417,075 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $16,436,130 | 3,417,075 | Shares | Sole | 2023-08-15 | |
| 2023-03-31 | $13,873,324 | 3,417,075 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $18,452,205 | 3,417,075 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $34,273,262 | 3,417,075 | Shares | Sole | 2022-11-09 | |
| 2022-06-30 | $16,060,252 | 3,417,075 | Shares | Sole | 2022-08-12 | |
| 2022-03-31 | $13,360,763 | 3,417,075 | Shares | Sole | 2022-05-13 | |
| 2021-12-31 | $23,099,427 | 3,417,075 | Shares | Sole | 2022-01-21 | |
| No filing history on record for this holder in this stock. | ||||||